questionText: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 October 2025 to Question 83204, what step he is taking to secure a recurrent budget for abiraterone in high risk, non-metastatic prostate cancer, in the context of it b
answerText: We are pleased to confirm that NHS England announced on 16 January that patients with non‑metastatic prostate cancer will now have access to abiraterone in combination with prednisolone, where it is deemed to be clinically beneficial. This development has...
heading: Abiraterone